Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T16:26:43.216Z.
Calculation as of: 2026-10-06T16:26:43.216Z.
Quote observation: 2026-10-06T16:25:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a99f3f088f54f9f9c0225e5104dac3e52b54f392bb47ad8d1f9af79329b73e7d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$4.37B
PS Ratio
20.59
TTM Avg
15.09
3Y Avg
15.20
5Y Avg
15.20
Market Cap
$4.39B
PS Ratio
14.25
TTM Avg
10.54
3Y Avg
6.93
5Y Avg
8.46
Market Cap
$4.09B
PS Ratio
395.30
TTM Avg
219.64
3Y Avg
131.28
5Y Avg
443.46
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edgewise Therapeutics, Inc. (EWTX) | $4.37B | N/A | N/A | N/A | N/A |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.37B | 20.59 | 15.09 | 15.20 | 15.20 |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.39B | 14.25 | 10.54 | 6.93 | 8.46 |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.42B | 3.32 | 3.55 | 2.38 | 2.56 |
| LivaNova PLC (LIVN)vs › | $4.15B | 2.82 | 2.71 | 2.39 | 2.70 |
| BillionToOne, Inc. (BLLN)vs › | $4.56B | 11.48 | 14.66 | 14.66 | 14.66 |
| AbCellera Biologics Inc. (ABCL)vs › | $4.13B | 62.35 | 31.32 | 30.27 | 21.11 |
| Relay Therapeutics, Inc. (RLAY)vs › | $4.09B | 395.30 | 219.64 | 131.28 | 443.46 |
| Option Care Health, Inc. (OPCH)vs › | $4.65B | 0.82 | 0.77 | 1.01 | 1.19 |
| LifeStance Health Group, Inc. (LFST)vs › | $4.69B | 2.96 | 2.20 | 2.14 | 2.77 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
